Antagonist properties of monoclonal antibodies targeting human CD28

mAbs

Volumn 5, Issue 1, 2013, Pages 47-55

  Mary, Caroline ^a,b   Coulon, Flora ^a   Poirier, Nicolas ^a,b   Dilek, Nahzli ^a,b   Martinet, Bernard ^a   Blancho, Gilles ^a,c   Vanhove, Bernard ^a,b,c  

^a INSERM   (France)

^b Effimune SAS   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Antagonist; CD28; Immunoglobulin; Immunotoxicity; Monovalent antibody

Indexed keywords

ALPHA 1 ANTITRYPSIN; CD3 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MACROGOL; MONOCLONAL ANTIBODY CD28; PHOSPHATIDYLINOSITOL 3 KINASE;

ACCESSORY CELL; ANTIBODY STRUCTURE; ARTICLE; CELL PROLIFERATION; CONJUGATION; CYTOKINE RELEASE; DRUG HALF LIFE; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; NONHUMAN; PROTEIN MULTIMERIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; FEMALE; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; POLYETHYLENE GLYCOLS; SINGLE-DOMAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 84872839388     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22697     Document Type: Article

References (31)

1. Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24:2-11; PMID:20964725; http://dx.doi.org/10.1111/j.1432-2277.2010.01176.x
2. Nogid A, Pham DQ Role of abatacept in the management of rheumatoid arthritis. Clin Ther 2006; 28:1764-78; PMID:17212998; http://dx.doi.org/10.1016/ j.clinthera.2006.11.020
3. Vincenti F, Larsen C P, Alberu J, Bresnahan B., Garcia VD, Kothari J, et al Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-7; PMID:21992533; http://dx.doi.org/10.1111/j.1600-6143.2011.03785. x
4. Poirier N, Blancho G, Vanhove B. CD28-specific immunomodulating antibodies: what can be learned from experimental models? Am J Transplant 2012; 12:1682-90; PMID:22471377; http://dx.doi.org/10.1111/j.1600-6143.2012.04032.x
5. Yao S, Zhu Y, Zhu G., Augustine M, Zheng L, Goode D.J., et al B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729-40; PMID:21530327; http://dx.doi.org/10.1016/j.immuni.2011.03.014
6. Butte MJ, Keir ME, Phamduy T.B., Sharpe AH, Freeman GJ Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-22; PMID:17629517; http://dx.doi.org/ 10.1016/j.immuni.2007.05.016
7. Haspot F, Séveno C, Dugast A.S., Coulon F., Renaudin K, Usal C, et al Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5:2339-48; PMID:16162181; http://dx.doi.org/10.1111/j.1600-6143.2005.01018.x
8. Raychaudhuri S.P., Kundu-Raychaudhuri S, Tamura K., Masunaga T, Kubo K, Hanaoka K., et al FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008; 128:1969-76; PMID:18337836; http://dx.doi.org/10.1038/jid.2008.38
9. Perrin PJ, June CH, Maldonado J.H., Ratts RB, Racke MK Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999; 163:1704-10; PMID:10415078
10. Zhang T, Fresnay S, Welty E., Sangrampurkar N, Rybak E, Zhou H., et al Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11:1599-609; PMID:21749640; http://dx.doi.org/10.1111/j.1600-6143.2011.03624.x
11. Poirier N, Azimzadeh AM, Zhang T, Dilek N., Mary C, Nguyen B, et al Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2:17ra10; PMID:20371478; http://dx.doi.org/10.1126/scitranslmed.3000116
12. Lühder F., Huang Y, Dennehy K.M., Guntermann C., Müller I, Winkler E., et al Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197:955-66; PMID:12707299; http://dx.doi.org/10.1084/jem.20021024
13. Arad G, Levy R, Nasie I., Hillman D, Rotfogel Z, Barash U., et al Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol 2011; 9:e1001149; PMID:21931534; http://dx.doi.org/10.1371/journal.pbio.1001149
14. Suntharalingam G, Perry MR, Ward S, Brett S.J., Castello-Cortes A, Brunner MD, et al Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-28; PMID:16908486; http://dx.doi.org/10.1056/NEJMoa063842
15. Vanhove B, Laflamme G, Coulon F., Mougin M, Vusio P, Haspot F., et al Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102:564-70; PMID:12649149; http://dx.doi.org/10.1182/blood-2002-08-2480
16. Shiao SL, McNiff JM, Masunaga T, Tamura K., Kubo K, Pober JS Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83:304-13; PMID:17297405; http://dx.doi.org/10.1097/01.tp.0000251426.46312.d5
17. Labrijn A.F., Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553
18. Liu YD, Chen X, Enk J.Z., Plant M., Dillon TM, Flynn GC Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283:29266-72; PMID:18713741; http://dx.doi.org/10.1074/jbc.M804787200
19. Yoo EM, Wims LA, Chan L.A., Morrison SL Human IgG2 can form covalent dimers. J Immunol 2003; 170:3134-8; PMID:12626570
20. Chapman A.P., Antoniw P, Spitali M., West S, Stephens S, King DJ Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17:780-3; PMID:10429243; http://dx.doi.org/10.1038/11717
21. Yu XZ, Bidwell SJ, Martin P.J., Anasetti C. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164:4564-8; PMID:10779758
22. Silver PB, Hathcock KS, Chan C.C., Wiggert B., Caspi RR Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000; 165:5041-7; PMID:11046033
23. Dengler TJ, Szabo G, Sido B., Nottmeyer W, Zimmerman R, Vahl C F, et al Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation 1999; 67:392-8; PMID:10030284; http://dx.doi.org/10.1097/00007890-199902150- 00009
24. Guillonneau C, Séveno C, Dugast A.S., Li XL, Renaudin K, Haspot F, et al Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179:8164-71; PMID:18056359
25. Haspot F, Villemain F, Laflamme G., Coulon F, Olive D, Tiollier J., et al Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99:2228-34; PMID:11877302; http://dx.doi.org/10.1182/blood.V99.6.2228
26. Poirier N, Mary C, Dilek N., Hervouet J, Minault D, Blancho G., et al Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012; 12:2630-40; PMID:22759318; http://dx.doi.org/10.1111/j.1600-6143.2012.04164.x
27. Jang MS, Pan F, Erickson L.M., Fisniku O., Crews G, Wynn C, et al A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway. Transplantation 2008; 85:1051-5; PMID:18408588; http://dx.doi.org/10.1097/TP.0b013e31816846f6
28. Clark M, Bindon C, Dyer M., Friend P, Hale G, Cobbold S., et al The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol 1989; 19:381-8; PMID:2522881; http://dx.doi.org/10. 1002/eji.1830190224
29. Poirier N, Blancho G, Vanhove B. Alternatives to calcineurin inhibition in renal transplantation: belata-cept, the first co-stimulation blocker. Immunotherapy 2010; 2:625-36; PMID:20874646; http://dx.doi.org/10.2217/imt.10.57
30. Smith BJ, Popplewell A, Athwal D., Chapman A P, Heywood S, West S.M., et al Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 2001; 12:750-6; PMID:11562193; http://dx.doi.org/10. 1021/bc010003g
31. Andres PG, Howland KC, Dresnek D, Edmondson S., Abbas AK, Krummel MF CD28 signals in the immature immunological synapse. J Immunol 2004; 172:5880-6; PMID:15128767